Amgen wants to buy Horizon Therapeutics to bolster is drug portfolio as it faces patent expirations. The FTC fears the deal could entrench monopoly positions.
You are here: Home / FTC sues to block Amgen acquisition of Horizon Therapeutics
Market News and Views
Amgen wants to buy Horizon Therapeutics to bolster is drug portfolio as it faces patent expirations. The FTC fears the deal could entrench monopoly positions.